表紙
市場調査レポート

肥満症:パイプライン製品の分析

Obesity - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232860
出版日 ページ情報 英文 544 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
肥満症:パイプライン製品の分析 Obesity - Pipeline Review, H1 2016
出版日: 2016年04月30日 ページ情報: 英文 544 Pages
概要

肥満症は、身体に過度の脂肪を蓄積した状態をいい、心臓病や糖尿病、高血圧などの疾患のリスクを高めます。素因には、年齢、家族歴、禁煙、睡眠不足、一部の投薬などがあり、健康的な生活、投薬、手術などの治療法があります。

当レポートでは、世界における肥満症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

肥満症の概要

治療薬の開発

肥満症:企業で開発中の治療薬

肥満症:大学/機関で研究中の治療薬

肥満症:パイプライン製品の概況

肥満症:企業で開発中の製品

肥満症:大学/機関で研究中の製品

肥満症の治療薬開発に従事している企業

肥満症:治療薬の評価

薬剤プロファイル

肥満症:最近のパイプライン動向

肥満症:休止中のプロジェクト

肥満症:開発が中止された製品

肥満症:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7684IDB

Summary

Global Markets Direct's, 'Obesity - Pipeline Review, H1 2016', provides an overview of the Obesity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Obesity
  • The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects
  • The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Obesity

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Obesity
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Obesity Overview
  • Therapeutics Development
  • Obesity - Therapeutics under Development by Companies
  • Obesity - Therapeutics under Investigation by Universities/Institutes
  • Obesity - Pipeline Products Glance
  • Obesity - Products under Development by Companies
  • Obesity - Products under Investigation by Universities/Institutes
  • Obesity - Companies Involved in Therapeutics Development
  • Obesity - Therapeutics Assessment
  • Drug Profiles
  • Obesity - Recent Pipeline Updates
  • Obesity - Dormant Projects
  • Obesity - Discontinued Products
  • Obesity - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Obesity, H1 2016
  • Number of Products under Development for Obesity - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Obesity - Pipeline by Abeome Corporation, H1 2016
  • Obesity - Pipeline by Advinus Therapeutics Ltd., H1 2016
  • Obesity - Pipeline by Aegis Therapeutics, LLC, H1 2016
  • Obesity - Pipeline by Akron Molecules AG, H1 2016
  • Obesity - Pipeline by Alize Pharma SAS, H1 2016
  • Obesity - Pipeline by Amabiotics SAS, H1 2016
  • Obesity - Pipeline by Ambrx, Inc., H1 2016
  • Obesity - Pipeline by Amgen Inc., H1 2016
  • Obesity - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Obesity - Pipeline by AstraZeneca Plc, H1 2016
  • Obesity - Pipeline by Asubio Pharma Co., Ltd., H1 2016
  • Obesity - Pipeline by AtheroNova Inc., H1 2016
  • Obesity - Pipeline by Athersys, Inc., H1 2016
  • Obesity - Pipeline by Avaxia Biologics, Inc., H1 2016
  • Obesity - Pipeline by BioLingus AG, H1 2016
  • Obesity - Pipeline by Biophytis SAS, H1 2016
  • Obesity - Pipeline by BioRestorative Therapies, Inc., H1 2016
  • Obesity - Pipeline by BioTime, Inc., H1 2016
  • Obesity - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Obesity - Pipeline by Braasch Biotech LLC, H1 2016
  • Obesity - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Obesity - Pipeline by Camurus AB, H1 2016
  • Obesity - Pipeline by Carmot Therapeutics, Inc., H1 2016
  • Obesity - Pipeline by Chronos Therapeutics Limited, H1 2016
  • Obesity - Pipeline by CohBar, Inc., H1 2016
  • Obesity - Pipeline by CoMentis, Inc., H1 2016
  • Obesity - Pipeline by Corium International, Inc., H1 2016
  • Obesity - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Obesity - Pipeline by Diabetica Limited, H1 2016
  • Obesity - Pipeline by DiscoveryBiomed, Inc., H1 2016
  • Obesity - Pipeline by Eisai Co., Ltd., H1 2016
  • Obesity - Pipeline by Eli Lilly and Company, H1 2016
  • Obesity - Pipeline by Esperion Therapeutics, Inc., H1 2016
  • Obesity - Pipeline by Eternygen GmbH, H1 2016
  • Obesity - Pipeline by Euroscreen S.A., H1 2016
  • Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Obesity - Pipeline by FibroGen, Inc., H1 2016
  • Obesity - Pipeline by Galenea Corp., H1 2016
  • Obesity - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Obesity - Pipeline by GTx, Inc., H1 2016
  • Obesity - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Obesity - Pipeline by Handok Inc., H1 2016
  • Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Obesity - Pipeline by Helsinn Healthcare S.A., H1 2016
  • Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016
  • Obesity - Pipeline by Immungenetics AG, H1 2016
  • Obesity - Pipeline by Intarcia Therapeutics, Inc., H1 2016
  • Obesity - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Obesity - Pipeline by Jenrin Discovery, Inc., H1 2016
  • Obesity - Pipeline by Johnson & Johnson, H1 2016
  • Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Obesity - Pipeline by Kowa Company, Ltd., H1 2016
  • Obesity - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Obesity - Pipeline by LEO Pharma A/S, H1 2016
  • Obesity - Pipeline by LG Life Science LTD., H1 2016
  • Obesity - Pipeline by Magnus Life Science, H1 2016
  • Obesity - Pipeline by MAKScientific, LLC, H1 2016
  • Obesity - Pipeline by MedImmune, LLC, H1 2016
  • Obesity - Pipeline by Merck & Co., Inc., H1 2016
  • Obesity - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016
  • Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Obesity - Pipeline by Molecular Design International, Inc., H1 2016
  • Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H1 2016
  • Obesity - Pipeline by Nimbus Therapeutics, LLC, H1 2016
  • Obesity - Pipeline by nLife Therapeutics, S.L., H1 2016
  • Obesity - Pipeline by Nordic Bioscience A/S, H1 2016
  • Obesity - Pipeline by Novo Nordisk A/S, H1 2016
  • Obesity - Pipeline by ObeTherapy Biotechnology, H1 2016
  • Obesity - Pipeline by Omeros Corporation, H1 2016
  • Obesity - Pipeline by OPKO Health, Inc., H1 2016
  • Obesity - Pipeline by Orbis Biosciences, Inc., H1 2016
  • Obesity - Pipeline by Orexigen Therapeutics, Inc., H1 2016
  • Obesity - Pipeline by Pfizer Inc., H1 2016
  • Obesity - Pipeline by PharmaIN Corporation, H1 2016
  • Obesity - Pipeline by Progenra, Inc., H1 2016
  • Obesity - Pipeline by Prometheon Pharma, LLC, H1 2016
  • Obesity - Pipeline by Reviva Pharmaceuticals Inc., H1 2016
  • Obesity - Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016
  • Obesity - Pipeline by Saniona AB, H1 2016
  • Obesity - Pipeline by Sanofi, H1 2016
  • Obesity - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016
  • Obesity - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Obesity - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016
  • Obesity - Pipeline by Sirona Biochem Corp, H1 2016
  • Obesity - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Obesity - Pipeline by Suven Life Sciences Ltd., H1 2016
  • Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Obesity - Pipeline by Toray Industries, Inc., H1 2016
  • Obesity - Pipeline by Transition Therapeutics Inc., H1 2016
  • Obesity - Pipeline by Umecrine AB, H1 2016
  • Obesity - Pipeline by Vicore Pharma AB, H1 2016
  • Obesity - Pipeline by Viking Therapeutics, Inc., H1 2016
  • Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016
  • Obesity - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016
  • Obesity - Pipeline by XL-protein GmbH, H1 2016
  • Obesity - Pipeline by Zafgen Inc., H1 2016
  • Obesity - Pipeline by Zealand Pharma A/S, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Obesity Therapeutics - Recent Pipeline Updates, H1 2016
  • Obesity - Dormant Projects, H1 2016
  • Obesity - Dormant Projects (Contd..1), H1 2016
  • Obesity - Dormant Projects (Contd..2), H1 2016
  • Obesity - Dormant Projects (Contd..3), H1 2016
  • Obesity - Dormant Projects (Contd..4), H1 2016
  • Obesity - Dormant Projects (Contd..5), H1 2016
  • Obesity - Dormant Projects (Contd..6), H1 2016
  • Obesity - Dormant Projects (Contd..7), H1 2016
  • Obesity - Dormant Projects (Contd..8), H1 2016
  • Obesity - Dormant Projects (Contd..9), H1 2016
  • Obesity - Dormant Projects (Contd..10), H1 2016
  • Obesity - Dormant Projects (Contd..11), H1 2016
  • Obesity - Dormant Projects (Contd..12), H1 2016
  • Obesity - Dormant Projects (Contd..13), H1 2016
  • Obesity - Dormant Projects (Contd..14), H1 2016
  • Obesity - Dormant Projects (Contd..15), H1 2016
  • Obesity - Dormant Projects (Contd..16), H1 2016
  • Obesity - Dormant Projects (Contd..17), H1 2016
  • Obesity - Dormant Projects (Contd..18), H1 2016
  • Obesity - Dormant Projects (Contd..19), H1 2016
  • Obesity - Dormant Projects (Contd..20), H1 2016
  • Obesity - Dormant Projects (Contd..21), H1 2016
  • Obesity - Discontinued Products, H1 2016
  • Obesity - Discontinued Products (Contd..1), H1 2016
  • Obesity - Discontinued Products (Contd..2), H1 2016
  • Obesity - Discontinued Products (Contd..3), H1 2016
  • Obesity - Discontinued Products (Contd..4), H1 2016
  • Obesity - Discontinued Products (Contd..5), H1 2016
  • Obesity - Discontinued Products (Contd..6), H1 2016

List of Figures

  • Number of Products under Development for Obesity, H1 2016
  • Number of Products under Development for Obesity - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top